Video
Dr. Tolaney Discusses Neratinib in HER2+ Breast Cancer
Author(s):
Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neratinib (Nerlynx) in HER2-positive breast cancer.
Although trastuzumab (Herceptin) remains the standard of care, the recent approval of neratinib could shake up treatment decisions for certain subgroups of breast cancer.
Related Videos
Related Content
